Abstract: Romidepsin (FK228) is a potent, cyclic depsipeptide and a selective class I histone deacetylase (HDAC) inhibitor. While it has achieved regulatory approval and significant clinical success in the treatment of hematological malignancies such as cutaneous and peripheral T-cell lymphomas (CTCL and PTCL), its efficacy as a monotherapy in solid tumors has been notably limited. Recent research directions have shifted toward utilizing romidepsin in combination therapies to overcome resistance and enhance anti-tumor immunity in solid tumors, including breast, prostate, colon, and lung cancers. This comprehensive review synthesizes the current literature on romidepsin in the context of solid tumors, detailing its pharmacological activity, molecular mechanisms of action, structure-activity relationship (SAR), current clinical limitations, and future perspectives focusing on synergistic combinations with chemotherapy and immunotherapy.
1. Introduction
Epigenetic modifications, particularly histone acetylation and deacetylation, play a crucial role in the regulation of gene expression and cancer progression. The balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) is frequently disrupted in malignancies, making HDACs a prime target for anticancer therapies [3]. Romidepsin (also known as FK228 or depsipeptide) is a natural cyclic tetrapeptide that functions as a highly potent epigenetic modulator [9]. It was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) in 2009 and peripheral T-cell lymphoma (PTCL) in 2011 [3][6].
Despite its established role in hematological malignancies, the application of romidepsin in solid tumors has presented significant challenges. Clinical trials evaluating romidepsin as a single agent in solid tumors have generally yielded disappointing results [5][9]. Consequently, the current research trajectory for romidepsin in solid tumors is heavily focused on combination strategies. By leveraging its ability to modulate the tumor microenvironment, enhance immune recognition, and sensitize cancer cells to cytotoxicity, romidepsin is being actively investigated in combination with immune checkpoint inhibitors and traditional chemotherapeutics for various solid malignancies [1].
2. Pharmacological Activity
The pharmacological evaluation of romidepsin in solid tumors has revealed distinct effects depending on whether it is used as a monotherapy or in combination regimens:
Breast Cancer: Romidepsin has shown significant promise in preclinical models of breast cancer when used in combination. In inflammatory breast cancer, romidepsin targets tumor emboli, impairs lymphatic vascular structures, and synergizes with paclitaxel to inhibit metastasis [1]. Furthermore, a triple combination regimen consisting of gemcitabine, romidepsin, and cisplatin has been formulated to safely and efficaciously control tumor development, recurrence, and metastasis in triple-negative breast cancer (TNBC) [1].
Prostate Cancer: The efficacy of romidepsin in prostate cancer has been evaluated in clinical settings. A phase II trial involving 35 patients with metastatic castration-resistant prostate cancer (CRPC) administered romidepsin intravenously at 13 mg/m2. The results showed that only two patients achieved a radiological partial response and a >50% decline in PSA lasting more than 6 months. Meanwhile, 22 patients showed disease progression, and 11 patients had to be taken off the treatment early due to toxicities. Based on these findings, romidepsin monotherapy was not recommended for CRPC [5].
Colon and Lung Cancers: In colon cancer models, romidepsin was found to regulate the expression of the immune checkpoint ligand PD-L1 and suppress cellular immune functions. However, this suppression was successfully abrogated by the addition of an anti-PD-1 antibody, suggesting a strong rationale for combination immunotherapy [1]. Similarly, in lung adenocarcinoma, romidepsin treatment upregulated the expression of chemokines, stimulated T-cell infiltration, and augmented the therapeutic response to PD-1 blockade [1].
Other Solid Tumors: Broadly, romidepsin has not been effective as a monotherapy in clinical studies involving neuroendocrine tumors, glioblastoma multiforme, mesothelioma, refractory colorectal, head and neck, renal cell, ovarian, cervical, and thyroid cancers [9].
3. Molecular Mechanism of Action
Romidepsin exerts its anticancer effects in solid tumors through multiple interconnected molecular pathways driven by its primary function as an HDAC inhibitor:
HDAC Inhibition and Cell Cycle Arrest: Romidepsin selectively inhibits class I HDACs (specifically HDAC1 and HDAC2). This inhibition leads to the hyperacetylation of histones (such as H3 and H4), which relaxes chromatin and reactivates silenced tumor suppressor genes. A key downstream effect is the upregulation of the p21 tumor-suppressor gene, which induces cell cycle arrest and preferentially mediates apoptosis in tumor cells [1][6].
Protein Degradation via HSP90: Beyond histones, romidepsin induces the hyperacetylation of non-histone proteins, notably the chaperone protein HSP90. The acetylation of HSP90 disrupts its function, leading to the degradation of client oncoproteins that require HSP90 for stability, such as mutant p53, RAF-1, and BCR-ABL [6].
Inhibition of Angiogenesis and Metastasis: Romidepsin downregulates the expression of angiogenic-stimulating factors, including VEGF and HIF-1a. By blocking the migration and adhesion of endothelial cells, it effectively inhibits neovascularization and tumor expansion, a mechanism particularly noted in inflammatory breast cancer [1][6].
Immunomodulation: Romidepsin significantly alters the tumor immune microenvironment. It enhances the acetylation of histones and modulates BRD4, which can upregulate PD-L1 expression. While this can temporarily suppress cellular immunity by increasing FOXP3+ regulatory T cells and reducing IFN-g+ CD8+ T cells, it simultaneously primes the tumor for immune checkpoint inhibitors (ICIs). When combined with anti-PD-1 therapy, romidepsin promotes T-cell infiltration and tumor regression [1].
4. Structure-Activity Relationship (SAR)
Romidepsin belongs to the cyclic tetrapeptide (bicyclic depsipeptide) class of HDAC inhibitors [5][9]. Its unique structural features are directly responsible for its potency and selectivity:
Prodrug Activation: Romidepsin functions as a natural prodrug. Its stable bicyclic structure allows it to enter the cell intact. Once inside the reductive intracellular environment, the critical disulfide bond within the depsipeptide is reduced, releasing a functional metabolite containing a free thiol (sulfhydryl) group [9].
Zinc Chelation: The newly exposed thiol group acts as a highly effective chelator. It reaches into the catalytic pocket of class I HDAC enzymes and tightly binds to the essential zinc ion (Zn2+) located in the active center. This chelation completely blocks the deacetylase activity of the enzyme [9]. The specific geometry of the cyclic peptide backbone provides romidepsin with a high degree of selectivity for class I HDACs over other classes, distinguishing it from pan-HDAC inhibitors like vorinostat or belinostat [6].
5. Current Limitations
Despite its targeted mechanism, the clinical translation of romidepsin for solid tumors faces several significant limitations:
Lack of Monotherapy Efficacy: The most glaring limitation is the failure of romidepsin to produce objective clinical responses as a single agent in solid tumors. Unlike hematological malignancies, solid tumors appear to possess intrinsic resistance mechanisms, potentially due to complex tumor microenvironments, redundant epigenetic pathways, or insufficient drug penetration into solid masses [3][5][9].
Adverse Events (AEs): Romidepsin treatment is associated with a challenging toxicity profile. Common adverse events include severe fatigue, gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation), and hematological toxicities such as thrombocytopenia, neutropenia, and lymphopenia [3][6][11]. Cardiac toxicity, phlebitis, and dyspnea have also been reported, which frequently lead to dose reductions or early termination of treatment in clinical trials [3][5].
Immune Evasion: As observed in colon cancer models, romidepsin can inadvertently upregulate PD-L1 and increase regulatory T cells, creating an immunosuppressive environment that protects the tumor unless counteracted by concurrent immunotherapy [1].
6. Future Perspectives
Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies remains of great importance [9]. The future of romidepsin in solid tumor oncology relies entirely on rational combination strategies:
Synergy with Immunotherapy: The ability of romidepsin to upregulate chemokines and PD-L1 provides a strong rationale for combining it with immune checkpoint inhibitors (ICIs). Preclinical data in lung and colon adenocarcinomas demonstrate that combining romidepsin with anti-PD-1 antibodies significantly improves T-cell infiltration and tumor regression, turning "cold" solid tumors into "hot" tumors responsive to immunotherapy [1].
Combination with Cytotoxic Chemotherapy: Romidepsin has shown the ability to sensitize solid tumors to traditional chemotherapeutics. Regimens such as the triple combination of gemcitabine, romidepsin, and cisplatin for TNBC, or romidepsin with paclitaxel for inflammatory breast cancer, represent promising avenues to overcome chemoresistance and inhibit metastasis [1].
Biomarker-Driven Approaches: Future clinical trials must focus on identifying predictive biomarkers to select patient populations most likely to benefit from romidepsin. Understanding the specific epigenetic mutations or immune profiles of a patient's solid tumor will be critical to maximizing efficacy and minimizing unnecessary exposure to toxicities [6].
